Lopinavir/Ritonavir/Lamivudine/Zidovudine

洛匹那韦/利托那韦/齐多夫定/拉米夫定

Report date: 2022/12/07 17:51:54

Base Information

Drug NameLopinavir/Ritonavir/Lamivudine/Zidovudine
Drug Alias NameLamivudine, Ritonavir, Zidovudine and Lopinavir拉米夫定•利托那韦•齐多夫定•洛匹那韦拉米夫定/齐多夫定/洛匹那韦/利托那韦Lamivudine/Ritonavir/Azidothymidine/LopinavirLamivudine-Ritonavir-Zidovudine-Lopinavir +[11] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsHuman immunodeficiency virus type 1 protease inhibitorsReverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseHuman immunodeficiency virus type 1 proteaseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUganda
CombinationsYes LamivudineZidovudineRitonavir
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCipla IncDrugs For Neglected Diseases Initiative
China Registration ClassN/A

Develop Information

Active CompaniesCipla IncDrugs For Neglected Diseases Initiative
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A